Allogene Therapeutics - ALLO Stock Forecast, Price & News

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALLO shares.
View ALLO analyst ratings or view top-rated stocks.

14 brokerages have issued 12-month price objectives for Allogene Therapeutics' stock. Their ALLO share price forecasts range from $11.00 to $43.00. On average, they expect the company's stock price to reach $27.62 in the next twelve months. This suggests a possible upside of 160.0% from the stock's current price.
View analysts price targets for ALLO or view top-rated stocks among Wall Street analysts.

Allogene Therapeutics' stock was trading at $14.92 at the beginning of 2022. Since then, ALLO shares have decreased by 28.8% and is now trading at $10.62.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ALLO earnings forecast.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) posted its quarterly earnings results on Tuesday, August, 9th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.09. Allogene Therapeutics had a negative net margin of 124,571.27% and a negative trailing twelve-month return on equity of 34.73%. During the same period last year, the firm posted ($0.53) EPS.

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Allogene Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Woodline Partners LP (4.07%), State Street Corp (3.93%), Price T Rowe Associates Inc. MD (3.87%), Primecap Management Co. CA (3.40%), JPMorgan Chase & Co. (3.14%) and Goldman Sachs Group Inc. (1.37%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends.

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALLO stock can currently be purchased for approximately $10.62.

Allogene Therapeutics (NASDAQ:ALLO) has a market capitalization of $1.53 billion and generates $38.49 million in revenue each year. The company earns $-257,010,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis.

The company employs 308 workers across the globe.

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.allogene.com. The company can be reached via phone at (650) 457-2700 or via email at ir@allogene.com.